. Author manuscript; available in PMC: 2016 Sep 1.

Published in final edited form as: Gastroenterology. 2015 Apr 24;149(3):567–576.e3. doi: 10.1053/j.gastro.2015.04.013

Table 4.

Progression Rates to HGD or Cancer from Time of Intervention^{^}

	Progressors / Non-progressors^*
Follow-up	Ablation	%^#	Surveillance	%^#
Yr 1	1 /32	3.0	16 / 92	14.8
Yr 2	0 / 26	0	11 / 68	13.9
Yr 3	0 / 21	0	2 / 56	3.4
Yr 4	0 / 15	0	4 / 46	8.0
Yr 5	0 / 9	0	0 / 45	0

= progressors within the yr / nonprogressors with at least that yr of follow-up

= progressors/ (nonprogressors with at least yr follow-up and progressors within that yr)

^{^}

Overall progression during follow-up period was 1 IMC (2.2%) in RFA group vs. 29 HGD, 5 IMC, and 2 submucosal EAC (28.8%) in surveillance group (P <0.001). Median time from initial intervention to progression to HGD or cancer was 7.5 months in RFA and 12.5 months (IQR: 7.4, 24.2) in surveillance. Progression to HGD or cancer when stratified by center as follows: University of Pennsylvania 1/5 RFA and 19/53 surveillance, Columbia 0/10 RFA and 4/37 surveillance, Mayo Clinic 0/30 RFA and 13/35 surveillance.